Core Viewpoint - Growth investors are increasingly focused on stocks with above-average financial growth, and identifying such stocks can be challenging. Halozyme Therapeutics (HALO) is highlighted as a promising growth stock due to its favorable growth metrics and strong Zacks Rank [1][2]. Earnings Growth - Halozyme Therapeutics has a historical EPS growth rate of 54.8%, with projected EPS growth of 40.9% for the current year, significantly outperforming the industry average of 19.1% [5]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 19.7%, which is notably higher than the industry average of -2.9%. Additionally, its annualized cash flow growth rate over the past 3-5 years stands at 48.7%, compared to the industry average of 2.5% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Halozyme Therapeutics, with the Zacks Consensus Estimate for the current year increasing by 0.9% over the past month, indicating strong near-term stock price movements [8]. Overall Positioning - Halozyme Therapeutics has achieved a Growth Score of B and a Zacks Rank 1 (Strong Buy), positioning it well for potential outperformance in the growth investment space [9][11].

Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic. The EC approval is based on pivotal data from the Phase III OCARINA II trial, which showed non-inferior levels of ...

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). "With this approval, CIDP patients in the U.S. will have access to the fi ...

Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator ...

Value Score Growth Score Momentum Score VGM Score How Style Scores Work with the Zacks Rank But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from. Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy. Stock to Watch: Halozyme Therapeutics (HALO) Momentum investors should take note of this Medical stock. H ...

However, Halozyme has clarified that its EPS guidance does not consider the impact of potential future share repurchases. Year to date, shares of HALO have rallied 39.2% against the industry's 3.8% decline. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 37.7%. Halozyme Therapeutics' (HALO ...

Core Viewpoint - Halozyme Therapeutics reported strong earnings for Q1 2024, with adjusted earnings surpassing estimates, although total revenues fell short of expectations. The company continues to show growth potential, particularly in royalty revenues and adjusted EBITDA. Financial Performance - Adjusted earnings for Q1 2024 were 79 cents per share, exceeding the Zacks Consensus Estimate of 69 cents, and up from 47 cents per share in the same period last year [2] - Total revenues increased by 21% year over year to $195.9 million, driven by higher royalty payments and milestone payments, but missed the Zacks Consensus Estimate of $202 million [3] - Royalty revenues reached $120.6 million, a 21% increase from the previous year, accounting for approximately 61.5% of total revenues [4] - Product sales were $58.6 million, down 3.6% from the prior year, missing estimates [5] - Revenues from collaborative agreements rose significantly to $16.7 million from $1.7 million year over year [5] - Adjusted EBITDA was $115.7 million, reflecting a 55.7% increase from the prior year [5] Cash Position - As of March 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $463.5 million, up from $336 million as of December 31, 2023 [6] 2024 Guidance - Halozyme expects total revenues for 2024 to be between $915 million and $985 million, indicating year-over-year growth of 10% to 19% [7] - Royalty revenues are anticipated to be in the range of $500 million to $525 million [7] - Adjusted EBITDA is projected to be between $535 million and $585 million, representing year-over-year growth of 26% to 37% [7] - The company forecasts adjusted earnings per share between $3.55 and $3.90, reflecting an improvement of 28% to 41% year over year [8] Market Sentiment - Estimates for Halozyme have been trending upward over the past month, indicating positive market sentiment [9] - The company holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [11] Industry Comparison - Halozyme operates within the Zacks Medical - Biomedical and Genetics industry, where competitor Moderna has seen a 27% gain over the past month despite reporting a significant revenue decline [12]

Based on this new patent grant, management believes that it will be able to maintain the original royalty rate for J&J's Darzalex SC, in the EU through March 2029. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology's 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 40.9%. Halozyme Therapeutics (HALO) announced that it has been granted a new p ...

Core Viewpoint - Halozyme Therapeutics, Inc. is raising its full year 2024 financial guidance and updating its 5-year financial outlook due to the grant of a new European patent covering its ENHANZE® rHuPH20 product, which is expected to enhance its revenue streams and protect royalty rates until March 6, 2029 [1][8][16]. Financial Guidance - Total revenue is projected to be between $935 million and $1,015 million, indicating a growth of 13% to 22% compared to 2023 [4][18]. - Royalty revenue is expected to range from $520 million to $555 million, reflecting a growth of 16% to 24% over 2023 [4][18]. - Adjusted EBITDA is forecasted to be between $555 million and $615 million, representing a growth of 30% to 44% compared to 2023 [4][18]. - Non-GAAP diluted earnings per share are anticipated to be between $3.65 and $4.05, showing a growth of 32% to 46% over 2023 [4][18]. Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of drugs [3][12]. - The company has impacted over 800,000 patients globally and has licensed its technology to major pharmaceutical companies including Roche, Takeda, and Pfizer [3][12]. - Halozyme's headquarters is located in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN [5].

Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on ...